Biotech · Private company · Irvine, CA, US
Immport Therapeutics, Inc.
Track this companyFree. Adds Immport Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Discovery of Group A Streptococcus antigens for development of broadly effective vaccine candidates to prevent non-invasive and invasive disease and emergence of antimicrobial resistanceFiscal year 2026 · $300KNIH RePORTER 1R43AI192098-01A1 · fetched Nov 12, 2026
- Identification of protective human monoclonal antibodies for passive immunization against CryptosporidiumFiscal year 2026 · $300KNIH RePORTER 1R43AI197630-01 · fetched Nov 12, 2026
- Optimizing immunogenicity of novel Cryptosporidium vaccine candidatesFiscal year 2026 · $300KNIH RePORTER 5R43AI192105-02 · fetched Nov 12, 2026
- A sensitive and specific serology test for evaluating potency of whole cell Pertussis vaccinesFiscal year 2026 · $292.3KNIH RePORTER 5R43AI195168-02 · fetched Nov 12, 2026
- Optimizing immunogenicity of novel Cryptosporidium vaccine candidatesFiscal year 2025 · $300KNIH RePORTER 1R43AI192105-01 · fetched Nov 12, 2026
- A sensitive and specific serology test for evaluating potency of whole cell Pertussis vaccinesFiscal year 2025 · $300KNIH RePORTER 1R43AI195168-01 · fetched Nov 12, 2026
- Humoral Immunity to Enteric Viruses among Infants and Mothers in BangladeshFiscal year 2025 · $80.9KNIH RePORTER 5R21AI185887-02 · fetched Nov 12, 2026
- Humoral Immunity to Enteric Viruses among Infants and Mothers in BangladeshFiscal year 2024 · $269.4KNIH RePORTER 1R21AI185887-01 · fetched Nov 12, 2026
- SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 InfectionsFiscal year 2024 · $300KNIH RePORTER 75N93024C00044-0-9999-1 · fetched Nov 12, 2026